Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMO | O15229 | 4/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360749 | 0.96 | TSHR (0.55) | TSHRKMOPDE4BHSD11B1HDAC3 | |
| SCHEMBL5849219 | 0.95 | HDAC3 (0.58) | TSHRKMOPDE4BHSD11B1HDAC3 | |
| SCHEMBL727064 | 0.89 | TSHR (0.59) | TSHRKMOHSD11B1SRD5A2 | |
| SCHEMBL4609783 | 0.86 | KMO (0.53) | TSHRKMOHSD11B1HDAC3HDAC4 | |
| SCHEMBL14775644 | 0.84 | TSHR (0.52) | TSHRKMOHSD11B1HDAC3HDAC4 | |
| SCHEMBL6361425 | 0.83 | HDAC3 (0.51) | KMOPDE4BHDAC3HDAC4HDAC1 | |
| SCHEMBL12327101 | 0.83 | TSHR (0.52) | TSHRKMOHSD11B1SRD5A2 | |
| SCHEMBL5255144 | 0.82 | KMO (0.50) | TSHRKMOHSD11B1HDAC3HDAC4 | |
| SCHEMBL634330 | 0.82 | HSD17B3 (0.58) | TSHRKMOHDAC3HDAC4HDAC1 | |
| SCHEMBL11548828 | 0.82 | KMO (0.50) | TSHRKMOHSD11B1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11376248-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200138810-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20050100902-A1 | 5-cyano-1h-indole derivatives as antagonist of the inerleukine-8 receptors | LABORATORIES FOURNIER S.A. (FR) | 2005-05-12 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6605633-B1 | Such as 5-Bromo-2-phenyl-1H-indole-3-butanoic acid | FOURNIER INDUSTRIE ET SANTE (FR) | 2003-08-12 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | KYNU, HAAO, HCAR2 | TSHR 4479/4885KMO 7/4885PDE4B 1433/4885 |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | TSHR 2238/4885KMO 2075/4885PDE4B 2591/4885 |
| US-11376248-B2 | Treatment of aneurysms | KYNU, HAAO, HCAR2 | TSHR 4479/4885KMO 7/4885PDE4B 1433/4885 |
| US-20200138810-A1 | TREATMENT OF ANEURYSMS | KYNU, HAAO, HCAR2 | TSHR 4479/4885KMO 7/4885PDE4B 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.